Skip to main content
NCBI home page
Scientific Reports logoLink to Scientific Reports
. 2017 Feb 3;7:41839. doi: 10.1038/srep41839

Molecular mutagenesis of ppGpp: turning a RelA activator into an inhibitor

Jelena Beljantseva 1,*, Pavel Kudrin 1,*, Steffi Jimmy 2,3, Marcel Ehn 4, Radek Pohl 4, Vallo Varik 1,2,3, Yuzuru Tozawa 5, Victoria Shingler 2, Tanel Tenson 1, Dominik Rejman 4,a, Vasili Hauryliuk 1,2,3,b
PMCID: PMC5291098  PMID: 28157202

Abstract

The alarmone nucleotide (p)ppGpp is a key regulator of bacterial metabolism, growth, stress tolerance and virulence, making (p)ppGpp-mediated signaling a promising target for development of antibacterials. Although ppGpp itself is an activator of the ribosome-associated ppGpp synthetase RelA, several ppGpp mimics have been developed as RelA inhibitors. However promising, the currently available ppGpp mimics are relatively inefficient, with IC50 in the sub-mM range. In an attempt to identify a potent and specific inhibitor of RelA capable of abrogating (p)ppGpp production in live bacterial cells, we have tested a targeted nucleotide library using a biochemical test system comprised of purified Escherichia coli components. While none of the compounds fulfilled this aim, the screen has yielded several potentially useful molecular tools for biochemical and structural work.

Bacteria employ an array of systems to sense their environment and respond to various stimuli. One of such systems is mediated via changes in the intracellular levels of alarmone nucleotides guanosine tetraphosphate (ppGpp) and pentaphosphate (pppGpp), collectively referred to as (p)ppGpp1,2. The nucleotides are synthesized by RelA/SpoT Homologue (RSH) enzymes3 via an in-line nucleophilic attack of the 3′-OH group of GDP (or GTP) on the β-phosphate of ATP4 (Fig. 1a). (p)ppGpp is a pleotropic intracellular effector targeting numerous unrelated molecular targets. It regulates transcription via direct interaction with two allosteric sites of Escherichia coli RNAP5,6,7; suppresses translation via binding to the GTP-binding pocket of ribosome-associated GTPases8,9,10, DNA replication via binding to the active site of DNA-dependent RNA polymerase primase DnaG11,12, and nucleotide biosynthesis via direct competition with nucleotide substrates of several enzymes involved in synthesis of GTP13 and ATP14. In addition, (p)ppGpp activates its own production via interaction with ribosome-dependent E. coli RSH RelA15.

Figure 1. (p)ppGpp synthesis and degradation by RelA-SpoT Homologue (RSH) enzymes and design of RSH inhibitors based on the ppGpp scaffold.

Figure 1

Open in a new tab

(a) RSH enzymes synthesize (p)ppGpp using ATP and GTP/GDP as substrates. Hydrolysis of (p)ppGpp regenerates GTP/GDP, accompanied by release of pyrophosphate (PPi). (b) Structure of the first-generation ppGpp-based RSH inhibitor 2′-deoxyguanosine-3′-5′-di(methylene bisphosphonate) or (10)26. (c) Structure of the second-generation ppGpp-based RSH inhibitor Relacin25 and its efficiency in inhibition of E. coli RelA in in vitro system from purified components15. N2-isobutyryl-guanine (GiBu) base modification is highlighted in red. The reaction mixture contained 30 nM RelA, 0.5 μM 70S, 100 μM ppGpp, 0.3 mM [3H]GDP and 1 mM ATP. RelA enzymatic activity (turnover, ppGpp synthesized per RelA per minute) is normalized to that in the absence of an inhibitor. Error bars represent standard deviations of linear regression estimates, each experiment was performed at least three times.

An acute increase in (p)ppGpp concentration – referred to as ‘the stringent response’ – orchestrates a survival program leading to increased virulence and antibiotic tolerance16. In E. coli, the stringent response induced by amino acid limitation is mediated by ribosome-associated RSH RelA which is strongly activated by the presence of deacylated tRNA in the ribosomal A-site17. Due to the central role of the (p)ppGpp in regulation of bacterial virulence16 and recently proposed connection to formation of antibiotic-tolerant persister cells18, (p)ppGpp-mediated signaling constitutes a promising target for development of novel antibacterials.

To date two approaches have been employed for the development of chemical tools to inhibit cellular (p)ppGpp production. First, synthetic cationic peptide 1018 and its derivatives were suggested to bind to (p)ppGpp directly and mark the nucleotide for degradation19,20. The 1018 peptide has a very pleotropic effect on cell physiology: in addition to targeting bacterial biofilm formation, it regulates innate immunity via modulation of macrophage differentiation and suppresses inflammation by attenuating pro-inflammatory cytokine production (reviewed in Mansour et al.21). Follow up studies have shown that, however promising as an antibacterial, 1018 is not a specific inhibitor of the stringent response22,23.

The second approach has targeted RSH enzymes directly using ppGpp-based synthetic inhibitors24,25,26. Redesigning the ppGpp scaffold for inhibition of intracellular RSH enzymes poses several problems. First, the molecule has to be more ‘drug-like’, i.e. less charged, more hydrophobic, and, preferably, simpler and smaller. Even though known antibiotics do not follow Lipinski’s ‘rule of five’ – they are larger, have more H-acceptor and H-donor groups and less hydrophobic (especially in the case of compounds targeting Gram-negative bacteria) than drugs in general27 – ppGpp is still a clear outlier when it comes to hydrophobicity: it has a calculated distribution-coefficient at pH 7.4, clogD7.4, of −13.87, which is more than ten clogD units lower than that of antibacterials on average. Second, in order to survive in the intracellular milieu, the molecule should be made considerably more resistant to chemical and enzymatic degradation. Third, conformational flexibility of 3′ and 5′ pyrophosphate moieties of ppGpp is critical for its interaction with target proteins28 imparting additional structural constraints on design of derivatives.

The ‘Wexselblatt’s bisphosphonate’ – or (10) – was the first step towards achieving these goals. It is considerably more chemically stable than ppGpp due to replacement of the oxygen atoms connecting the phosphate groups with methylene bridges (Fig. 1b)26. However, the compound is relatively inefficient, requiring 1 mM concentration for 50% inhibition of E. coli RelA in the test tube, and is extremely hydrophilic (predicted theoretical clogD7.4 = −3.18 ± 0.85 using ACD/Labs package), rendering it inactive against live bacteria. The second-generation inhibitor Relacin is a more dramatic modification of the ppGpp scaffold: the pyrophosphate groups are replaced by diglycine moieties and the guanine base has a 2-N-isobutyryl (iBu) protecting group attached to the exocyclic amino group at C-2 position (Fig. 1c)24,25. The resultant compound is significantly less hydrophilic than ppGpp (theoretical clogD7.4 = −7.95 ± 1.03), and at mM-range concentrations has a biological effect on Gram-positive bacterium Bacillus subtilis26.

However promising, the ppGpp-analogues developed to date are still far from entering the drug development pipeline due to their low potency, requiring concentrations of ≈1 mM to achieve significant inhibition of RSH enzymes24,25. Therefore, we have undertaken a targeted screen for more potent nucleotide-based RSH inhibitors using our biochemical in vitro system comprised of purified E. coli components15.

Results

For the initial characterization of compounds, we followed the inhibition of [3H] GDP conversion to [3H] ppGpp catalyzed by E. coli RelA in a simplified system in which RelA’s activity was induced by vacant 70S ribosomes and 100 μM of ppGpp15. Unlabeled ppGpp was added to reaction mixtures in order to linearize the kinetics of [3H] ppGpp synthesis due to an activating effect on the RelA enzyme15. We used a targeted library of 69 nucleotides belonging to several structural classes: ‘true’ ppGpp analogues; Relacin and its derivatives; pyrrolidine, azetidine, piperidine and acyclic phosphonates. Chemical structures of tested compounds and titrations in the RelA:70S:ppGpp system are presented in Supplementary Table 1.

A targeted screen for nucleotide-based RelA inhibitors

RSH inhibitors based on the ppGpp molecular scaffold

This class of compounds is unlikely to yield RSH inhibitors active against live bacteria since the exceedingly hydrophilic ppGpp scaffold is likely to compromise the pharmacokinetic properties. Nevertheless, a potent and specific ppGpp-based RSH inhibitor that acts in the test tube is useful, since it could i) serve as molecular tool for biochemical and structural studies and ii) be used to generate Structure-Activity Relationship (SAR) data instructive for development of inhibitors based on other molecular scaffolds. As a reference, we characterized ppGpp itself (Fig. 2a). In agreement with our earlier observations15, up to 100 μM of ppGpp activates RelA’s enzymatic activity, while at higher concentrations ppGpp acts as a weak inhibitor of RelA with an IC50 of 0.72 ± 0.44 mM.

Figure 2. Inhibition of E. coli RelA by ppGpp, ppGpp-based compounds and Relacin derivatives.

Figure 2

Open in a new tab

The reaction mixture contained 30 nM RelA, 0.5 μM 70 S, 100 μM ppGpp, 0.3 mM [3H]GDP and 1 mM ATP. RelA enzymatic activity (turnover, ppGpp synthesized per RelA per minute) is normalized to that in the absence of an inhibitor. Error bars represent standard deviations of linear regression estimates, each experiment was performed at least three times. (a) ppGpp activates RelA at low concentrations (<50 μM) and acts as a weak inhibitor at higher concentrations. (b) Addition of N2-isobutyryl guanine base modification present in Relacin (highlighted in red) to DR-4250 yielding DR4239 does not dramatically alter the activity. Removal of 2′ hydroxyl group from DR-4250 yielding DR-6241A (Supplementary Table 1) and bis (phosphonoacyl) analogue DR-6331 yielding DR-5799C significantly decreases the activity. (c) Substitution of the base in ppGpp for adenine yielding ppApp or 6-thio-guanine yielding thio-ppGpp results in a dramatic increase in the efficiency of RelA inhibition (d) SAR elements characteristic for RelA inhibition by ppGpp-based inhibitors (b,c) are not transferable to Relacin scaffold: removal of the N2-isobutyryl protective group yielding di-iBu-Relacin compromises its activity against RelA and substitution of guanine for 6-thio-guanine yielding thio-di-iBu-Relacin leads to a complete inactivation.

As a first step, we tested several modifications of the phosphate moieties of the scaffold. While several variants of non-hydrolysable ppGpp mimics relying on the modifications of the pyrophosphate moieties have been reported26, these compounds are relatively inefficient. The most potent representative, 2′-deoxyguanosine-3′-5′-di(methylene bisphosphonate) or (10), has an IC50 of ≈1 mM26 (Fig. 1b). In an attempt to improve the efficiency, we synthesized a set of derivatives in which the pyrophosphate moieties of ppGpp were replaced with phosphonomethyloxy (PCH2O-), phosphonoacetyl (PCH2CO-), phosphonopropionyl (PCH2CH2CO-), phosphonomethylaminocarbonyl (PCH2NHCO-), and phosphonomethyloxyphosphate (PCH2OPO-) groups (Supplementary Table 1). The most efficient inhibitor from this set is DR-4250 (IC50DR-4250 = 54 ± 3 μM) (Fig. 2b). The compound differs from ppGpp by the presence of methylene bridges (-CH2) adjoining the β-phosphorus atom and pyrophosphate bridging oxygen atom (PCOP). While structurally very similar to (10) in which methylene bridges replace the bridging oxygen atom, DR-4250 is an order of magnitude more potent inhibitor of RelA. A 2′-deoxy derivative DR-6241A has reduced activity (IC50DR-6241A = 0.47 ± 0.18 mM) and further removal of 3′-pyrophosphate moiety yields even less potent DR-6222 (IC50DR-6222 = 0.73 ± 0.06 mM) (Supplementary Table 1). In order to reduce the net charge of DR-4250 we removed both phosphate groups generating bis (phosphonomethyl) derivative DR-6331. With an IC50 of 76 ± 6 μM the compound is, surprisingly, nearly as active as parental DR-4250 (Fig. 2b). From the medicinal chemistry point of view the structure of DR-6331 is promising for further derivatization because of first, chemical and enzymatic stability due to absence of pyrophosphate or phosphate ester functions and, second, possibility of conversion to a prodrug form with masked negative charges. Similarly to DR-4250, removal of the 2′ OH group of DR6331 yields a significantly less active 2′-deoxyguanosine derivative DR-5799C with IC50 of 515 ± 392 μM (Fig. 2b), underscoring the functional importance of 2′ hydroxyl group. We have synthesized and tested five additional bis (phosphonoacyl) analogues; however, none of these compounds are active against RelA (Supplementary Table 1).

We next tested several ppGpp analogues containing a modified nucleotide base. The molecular mechanism by which ppGpp activates RelA’s synthetic activity is unclear15. To test the specificity of the effect, we synthesized an adenine derivative of ppGpp, ppApp. The 6-thioguanosine derivative of ppGpp, 6-thio-ppGpp, is a UV-inducible zero-length crosslinking reagent that was successfully used to map the two ppGpp binding sites of E. coli RNAP6,29, suggesting that a similar approach could potentially be used to map the ppGpp binding site of RelA. Surprisingly, unlike ppGpp, neither ppApp nor 6-thio-ppGpp activate RelA’s synthetic activity (Supplementary Figure 1). On the contrary, both compounds are potent inhibitors with IC50 of 24.5 ± 3.5 μM and 21.3 ± 2.1 μM, respectively (Fig. 2c). The only nucleotide-based RSH inhibitor that showed activity against bacterial cultures, Relacin, has N2-isobutyryl-guanine (GiBu) modification of the nucleotide base25. This modification is a common protective group used in nucleotide chemistry30. The original publication did not explain the rationale behind using this modification – Is it important for the SAR of the inhibitor? Is it merely a result of the omission of the deprotection stage due to technical difficulties? – Therefore, we synthesized and tested several GiBu-modified compounds and found that replacement of the G base in DR-4250 with GiBu slightly decreases its activity (IC50DR-4239 = 101 ± 8 μM) (Fig. 2b).

Finally, we attempted to apply the structural alterations listed above to Relacin. As an initial step we tested Relacin itself. In good agreement with earlier estimates25,31, the compound is relatively inefficient with IC50 of 0.84 ± 0.2 mM (Fig. 1c). Next, we tested the effect of the removal of the iBu protection group from guanine residue of Relacin. This resulted in a near-complete inactivation of the compound (Fig. 2d), demonstrating that iBu is crucial for Relacin’s activity against RelA. When we replaced the GiBu in the Relacin scaffold with 6-thio-G, the resulting molecule DR-5732 had virtually no activity (Fig. 2d).

Guanosine phosphonates

The sugar-phosphate moiety of ‘true’ ppGpp-based RSH inhibitors poses a significant hurdle for medicinal chemistry because it is large, complex, and highly charged. Therefore we attempted to develop a simpler and less charged nucleotide phosphonate structural backbone as a platform for future derivatization. This class of compounds has generated efficient inhibitors of various classes of evolutionary unrelated enzymes such as viral DNA polymerases32 and malarial hypoxanthine-guanine-xanthine phosphoribosyltransferase33.

We assembled and tested a targeted library of structurally diverse guanine nucleoside phosphonates (see Supplementary Table 1)34,35,36,37,38. In this compound series – piperidine, pyrrolidine, prolinol, azetidine and acyclic phosphonates – the size of the heterocyclic amine ring is progressively smaller, decreasing from a six-membered ring to a linear molecule. Out of the 12 piperidine phosphonates, the most potent inhibitor is DR-M014 with an IC50 of 121 ± 20 μM (Fig. 3a). Replacement of the phosphonocarbonyl group for phosphonoacetyl resulted in a less efficient compound DR-M011 (IC50 = 234 ± 67 μM). Out of 21 pyrrolidine phosphonates tested, the most potent inhibitor is DR-4520 with an IC50 of 200 ± 22 μM, which is almost twice less efficient than the most potent piperidine phosphonate, DR-M014 (Fig. 3b). An enantiomeric pyrrolidine phosphonate DR-5267B (R), which differs from DR-4520 (an 3-C S isomer) by the configuration of the 3-C carbon atom of the pyrrolidine ring, is significantly less active (IC50DR-5267B = 652 ± 194 μM vs IC50DR-4520 = 200 ± 22 μM), pointing towards the specificity of inhibition. As was the case for DR-M014, the phosphonocarbonyl group is important for the activity of DR-4520: a mono-isopropylester modification results in a near-inactive compound DR-4518 (IC50 = 1.71 ± 0.66 mM) (Fig. 3b). Modification of the pyrrolidine ring by the addition of hydroxymethyl group at C-2 to afford 2-pyrrolidinemethanol (prolinol) resulted in inactivation of the compound (Supplementary Table 1). An acyclic scaffold is highly advantageous from the synthetic chemistry viewpoint due to the absence of stereoisomeric centers, thus eliminating the need for stereospecific synthesis. Out of three tested acyclic phosphonates, the most active representative – DR-5163 – inhibits RelA in our biochemical system with an IC50 of 245 ± 39 μM (Fig. 3c). Replacement of the phosphonocarbonyl group in DR-5163 by phosphonoacetyl results in a dramatically less active compound DR-5164 (IC50DR-5164 = 1.4 ± 0.12 mM) (Fig. 3c).

Figure 3. Inhibition of E. coli RelA by guanosine phosphonates.

Figure 3

Open in a new tab

The reaction mixture contained 30 nM RelA, 0.5 μM 70 S, 100 μM ppGpp, 0.3 mM [3H]GDP and 1 mM ATP. RelA enzymatic activity (turnover, ppGpp synthesized per RelA per minute) is normalized to that in the absence of an inhibitor. Error bars represent standard deviations of linear regression estimates, each experiment was performed at least three times. (a) RelA inhibition by piperidine phosphonate DR-M014 containing phosphonocarbonyl group and DR-M011 containing phosphonoacetyl. (b) Inversion of the stereocenter in the C-3 position of the pyrrolidine ring of pyrrolidine phosphonate DR-4520 (yielding DR-5267B) or mono-isopropylester modification of the phosphonocarbonyl group (yielding DR-4518) decreases its activity. (c) Substitution of phosphonocarbonyl group in acyclic phosphonates DR-5163 by phosphonoacetyl yielding in DR-5164 results in a significant loss of activity against RelA. (d) Phosphonoformate or Foscarnet39 does not inhibit RelA despite the presence of a phosphonocarbonyl moiety.

The presence of a phosphonocarbonyl moiety is a recurring feature of the active phosphonate inhibitors tested so far. Hydrolysis of the amide bond would result in the formation of phosphonoformic acid. This compound, marketed as Foscarnet, is a well-characterized inhibitor of viral DNA polymerase by acting as a substrate analog mimicking the pyrophosphate moiety of NTP39. Because both the substrates and products of RSH enzymes contain pyrophosphate, it is likely that the same mechanism is at play in the case of active phosphonates such as DR-M014, DR-4520 and DR-5163. We tested the effect of phosphonoformic acid in our system, and by itself, it has virtually no inhibitory activity at concentrations up to 1 mM (Fig. 3d).

Naturally occurring nucleotides

There are several examples of direct cross-talk between bacterial nucleotide-based signaling systems, connecting ppGpp and c-di-AMP40, and cyclic GMP and cyclic di-GMP41 regulatory networks. Therefore, we tested a set of common signaling nucleotides and nucleotide cofactors: c-di-AMP, c-di-GMP, c-di-GAMP, NADH, NADPH. None of the compounds showed any inhibitory effect on E. coli RelA in concentration up to 1 mM (Supplementary Table 1).

Characterization of the promising RSH inhibitors

For the analysis of the mechanism of action, we selected the ‘true’ ppGpp analogue DR-4250, the most potent piperidine phosphonate DR-M014, and the most extensively characterized RSH inhibitor to date, Relacin25,31.

Inhibition of RelA activated by programmed ‘starved’ ribosomal complexes

Screening was performed in a cost-efficient way using RelA activated by the presence of vacant 70S ribosomes and 100 μM ppGpp. However, to become fully active, RelA requires the presence of ‘starved’ ribosomal complexes containing deacylated A-site tRNA17. We therefore prepared ‘starved’ complexes using model mRNA coding for fMetPhe (MF) dipeptide and purified deacylated tRNAs tRNAPhe and tRNAfMeti42 to test the efficiency of DR-4250 and DR-M014 in this more physiologically relevant system (Fig. 4a,b). DR-4250 and DR-M014 display similar efficiency in both systems (IC50DR-4250, 70S = 54 ± 3 μM vs. IC50DR-4250, 70S(MF:tPhe) = 41 ± 7 μM; IC50DR-M014, 70S = 121 ± 20 vs. IC50DR-M014,70S(MF:tPhe) = 155 ± 14 μM), suggesting a possibility for the compounds to be efficient in live cells.

Figure 4. Functional studies of DR-M014 and DR-4250 with programmed ribosomal complexes.

Figure 4

Open in a new tab

(a,b) Inhibition of RelA activated by starved ribosomal complexes containing deacylated A-site tRNAPhe. The reaction mixture contained 30 nM RelA, 0.5 μM 70S, 2 μM tRNAPhe, 2 μM tRNAiMet, 2 μM mRNA(MF), 100 μM ppGpp, 0.3 mM [3H] GDP and 1 mM ATP. The experiments were performed in HEPES:Polymix buffer with 5 mM Mg2+. Error bars represent standard deviations of linear regression estimates, each experiment was performed at least three times. (c) A-site tRNAPhe and nucleotides DR-M014 and DR-4250 promote RelA binding to 70S initiation complexes. The panel shows two independent experimental replicates. Reaction mixture containing combinations of 2 μM RelA, 1 μM 70S initiation complexes programmed with mRNA(MF), 3 μM deacylated tRNAPhe and test compounds at 500 μM was preincubated at 37 °C for 15 minutes prior to loading 50 μl samples on top of a 50 μl 30% sucrose cushion. After centrifugation for 25 minutes (70,000 r.p.m. at 12 °C) the supernatants were quickly aspirated, the pellets resuspended in 20 μl of SDS loading buffer, and the proteins resolved on 10% SDS-PAGE gel.

The ppGpp-analogues reported earlier promote RelA association with 70S ribosome25,26 and are, therefore, promising tools for generating stable 70S:RelA complexes for structural investigations. We tested DR-4250 and DR-M014 using a modified version of a spin down assay of Agirrezabala and colleagues43, using initiation complexes (IC) programmed with MetPhe mRNA, (MF), in the presence and absence of deacylated A-site tRNAPhe, and in the presence and absence of inhibitor (Fig. 4c). In a good agreement with earlier results, the presence of A-site deacylated tRNA strongly promotes RelA binding to the ribosome43, resulting in a stoichiometry of RelA to ribosomal protein S1 close to unity. Addition of 500 μM DR-4250 has virtually no effect on RelA binding, while DR-M014 significantly promotes RelA binding to the IC in the absence of tRNAPhe.

DR-M014 and DR-5163 are inefficient inhibitors of Enterococcus faecalis SAS RelQ

In E. coli, ppGpp is synthesized by the multi-domain RSHs RelA and SpoT, however, numerous single-domain RSHs – Small Alarmone Synthetases (SAS) – are widely distributed across bacterial taxa3. We found earlier that E. faecalis SAS RelQ (RelQEf) is virtually insensitive to Relacin31. Therefore we tested the effects of DR-4250, DR-M014 and DR-5163 on RelQEf activity (Supplementary Figure 2). While DR-M014 and DR-5163 were almost inactive at concentrations up to 1 mM, DR-4250 did inhibit RelQEf (IC50RelQ = 235 ± 19 μM), though significantly less efficient than E. coli RelA.

Off-target effects: inhibition of E. coli EF-G GTPase and RNA Polymerase

Since (p)ppGpp targets numerous enzymes, it is likely that a compound based on this scaffold would be a promiscuous binder as well. This promiscuity can be viewed as an advantage (e.g. because it would be harder for a bacteria to gain resistance by simultaneously altering several binding sites) or as a disadvantage (e.g. lack of strict specificity would render the inhibitor less useful as a molecular tool). Therefore, it is instrumental to test the off-target effects of the potential inhibitors.

Initially, we tested the effect of the most promising compounds on GTPase activity of EF-G stimulated by 70S ribosomes. We detected no inhibitory effect of Relacin (up to 5 mM), DR-4250, DR-M014, DR-5191B and DR-5163 (all up to 1 mM) or ppApp (up to 100 μM) (Supplementary Figure 3). Next, we tested their effects on RNAP. In E. coli, effects of ppGpp on RNAP are augmented by the transcription initiation factor DksA44. This small protein binds to the secondary channel of RNAP45,46 – a tunnel via which NTPs are delivered to enzyme’s active center47. The interaction affects transcriptional initiation via stimulation of an isomerization step in the pathway leading to open complex formation in a promoter-specific manner44 and increases the fidelity of transcription elongation48. We used multiple round in vitro transcription driven from the rrnB P1, a well-characterized ppGpp/DksA inhibited promoter, as described earlier49. The assays were performed in the presence and absence of 2 μM DksA and/or 100 μM ppGpp (Fig. 5a). When added at concentrations up to 5 mM, Relacin had a mild inhibitory effect, regardless of the presence and absence of DksA and ppGpp. Both DR-4250 and DR-M014 had a very different effect on RNAP (Fig. 5b,c). In the absence of DksA, irrespective of the presence or absence of ppGpp – both components were more potent inhibitors of RNAP then of RelA – and addition of DksA had a pronounced protective effect (compare Figs 4a,b and 5b,c). The intrinsically ppGpp-insensitive promoter rna144 displayed the same behavior (Supplementary Figure 4).

Figure 5.

Figure 5

Open in a new tab

Inhibition of multiple round in vitro transcription reaction by Relacin (a), DR-4250 (b) and DR-M014 (c). Effect of inhibitors on rrnB P1 (−66 to +50) promoter transcription by RNAP. Graphs depicting inhibitor (0, 0.025, 0.05, 0.15, 0.4 and 0.6 mM) titrations performed at 30 °C in T-buffer with 0.5 nM template (σ70-rrnB P1 promoter (pRLG6214)) and 5 nM σ70-RNAP, in presence or absence of 100 μM ppGpp and/or 2 μM DksA. Error bars represent standard deviations of linear regression estimates, each experiment was performed at least three times.

DR-4250, DR-5163 or DR-M014 do not act on live B. subtilis cultures

Finally, we tested the three of our most promising inhibitors (DR-4250, DR-M014 and DR-5163) for RSH inhibition in bacterial culture. For this we used the Gram-positive bacterium B. subtilis due to its better uptake of compounds as compared to Gram-negative species such as E. coli50. The functional test for RSH inhibition relied on the auxotrophy of (p)ppGpp-deficient (ppGpp0) B. subtilis for methionine and branched-chain amino acids valine, leucine and isoleucine51,23. The B. subtilis RSH repertoire consists of one multi-domain ribosome-associated enzyme Rel and two SAS, YwaC and YjbM3,52. Because the SAS RelQEf is refractory to inhibition by our test compounds (Supplementary Figure 2), we used a B. subtilis strain lacking SASs (ΔywaCΔyjbM), in which the sole source of (p)ppGpp is Rel53. Defined S7 medium54 lacking valine supports the growth of ΔywaCΔyjbM B. subtilis, but not the ppGpp0 stain (Supplementary Figure 5). Addition of increasing concentrations of DR-4250, DR-5163 or DR-M014 (up to 1 mM) does not affect the growth of ΔywaCΔyjbM B. subtilis in valine drop-out medium S7. This is indicative of the test compounds failing to inhibit Rel and thereby rendering the strain phenotypically ppGpp0 (Supplementary Figure 5). A lack of cellular uptake is a likely explanation.

Discussion

In this project we have screened a targeted nucleotide library – a total of 69 compounds – aiming to identify a potent and specific inhibitor of RSH enzymes capable of abrogation of (p)ppGpp production in bacterial culture. While none of the compounds fulfilled this aim, the screen has yielded several potentially useful molecular tools for biochemical and structural work, as well as highlighted the role of the transcription factor DksA in RNAP fidelity. DksA binds to the secondary channel via which nucleotides enter the catalytic center of the RNAP46 and counteracts the misincorporation events48. The higher fidelity of RNAP:DksA – and, therefore, better discrimination against nucleotide compounds that can not serve as substrates – is likely to be responsible for the protective effect of DksA against DR-4250 and DR-M014 in in vitro transcription assays (Fig. 5).

Recent structures of E. coli RelA complexed with ‘starved’ ribosomal complexes are instrumental to our understanding of the protein’s mechanism on the molecular level42,55. These cryo-electron microscopy (cryo-EM) reconstructions are, however, incomplete: the highly mobile N-terminal catalytic domain is unresolved and that part of the structural model was based on earlier crystal structure of truncated Rel enzyme from Streptococcus dysgalactiae subsp. equisimilis4. The incompleteness of the cryo-EM structure compromises its predictive power for structure-based design of selective RelA inhibitors. ppGpp-analogues were shown to promote RelA’s association with the 70 S ribosome25,26; we see similar effects for DR-M014 and DR-4250 (Fig. 5). Therefore, this kind of compounds could assist the generation of better-resolved cryo-EM structures by both stabilizing RelA’s structure and promoting it’s binding to starved ribosomal complexes. However, one should be cautious when interpreting the structural data generated using ppGpp mimics. As we show, when interacting with E. coli RelA, photoreactive ppGpp analogue 6-thio-ppGpp behaves radically differently from ppGpp: the base modification converts ppGpp from an activator to potent inhibitor of RelA (Fig. 2c). 6-thio-ppGpp is an exceedingly useful molecular tool that was recently used to identify the two ppGpp binding sites of E. coli RNAP6,29. Importantly, both of the binding sites were confirmed by mutagenesis; validation of that kind is essential to ensure the meaningfulness of the crosslinking data. One of the most potent RelA inhibitors identified in the current study is ppApp (Fig. 2c). This nucleotide is naturally produced by a divergent SAS RSH3 from Streptomyces morookaensis56. Since ppApp does not have a pronounced inhibitory effect on either transcription or translation in E. coli reconstituted systems57, it has a potential as a starting point for the development of a specific RSH inhibitor.

Methods

Detailed description of experimental procedures can be found in Supplementary Text. Biochemical assays utilize in vitro translation58 and stringent response15 systems from E. coli purified components. Experiments were performed in HEPES:Polymix58 buffer with either 5 (for enzymatically assembled initiation complexes) or 15 mM (for vacant 70 S, as well as non-enzymatically assembled programmed ribosomes) Mg2+. Expression and purification of E. faecalis RelQ was performed as per Gaca (2015) and colleagues31. GTPase and ppGpp synthesis were followed using TLC separation and radiochemical detection of 3H-labelled nucleotides59. Multiple round in vitro transcription assays were performed as per Bernardo et al.49 with minor modifications. Inhibition efficiency (IC50) was calculated using 4-parameter logistic model (Hill equation) as per Sebaugh60.

Additional Information

How to cite this article: Beljantseva, J. et al. Molecular mutagenesis of ppGpp: turning a RelA activator into an inhibitor. Sci. Rep. 7, 41839; doi: 10.1038/srep41839 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Supplementary Information
srep41839-s1.pdf (2.7MB, pdf)

Acknowledgments

We are grateful to Liis Andresen for setting up the B. subtilis growth assays. This work was supported by the funds from European Regional Development Fund through the Centre of Excellence in Molecular Cell Engineering (VH and TT), Estonian Research Council grants (PUT37 to VH, IUT2–22 to TT); Umeå University, Swedish Research council (2013–4680 to VH and 2011-4791 to VS), Ragnar Söderberg and Kempe foundations (VH); Czech Science Foundation grant number 15-11711S (DR). Collaboration between VH, YT and DR labs was supported by grant 202100-2874 from the Swedish foundation for international cooperation in research and higher education (STINT).

Footnotes

The authors declare no competing financial interests.

Author Contributions V.H. and D.R. conceived the study. V.H. coordinated the study, and drafted the manuscript with input from D.R., P.K., J.B., S.S. and T.T., V.H., J.B., V.S. and P.K. designed experiments and analyzed the data. D.R. and M.E. performed organic synthesis. R.P. characterized intermediates and final compounds by means of NMR techniques, and D.R. and M.E. performed analytical and preparative HPLC. J.B., P.K. and S.J. performed biochemical experiments. V.V. performed bacterial growth assays. T.T., Y.T. and V.S. provided materials. All authors have read and approved the manuscript as submitted.

References

  1. Hauryliuk V., Atkinson G. C., Murakami K. S., Tenson T. & Gerdes K. Recent functional insights into the role of (p)ppGpp in bacterial physiology. Nat Rev Microbiol 13, 298–309 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Liu K., Bittner A. N. & Wang J. D. Diversity in (p)ppGpp metabolism and effectors. Curr Opin Microbiol 24, 72–79 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Atkinson G. C., Tenson T. & Hauryliuk V. The RelA/SpoT homolog (RSH) superfamily: distribution and functional evolution of ppGpp synthetases and hydrolases across the tree of life. PLoS One 6, e23479 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hogg T., Mechold U., Malke H., Cashel M. & Hilgenfeld R. Conformational antagonism between opposing active sites in a bifunctional RelA/SpoT homolog modulates (p)ppGpp metabolism during the stringent response. Cell 117, 57–68 (2004). [DOI] [PubMed] [Google Scholar]
  5. Toulokhonov I. I., Shulgina I. & Hernandez V. J. Binding of the transcription effector ppGpp to Escherichia coli RNA polymerase is allosteric, modular, and occurs near the N terminus of the beta’-subunit. J Biol Chem 276, 1220–5 (2001). [DOI] [PubMed] [Google Scholar]
  6. Ross W., Vrentas C. E., Sanchez-Vazquez P., Gaal T. & Gourse R. L. The magic spot: a ppGpp binding site on E. coli RNA polymerase responsible for regulation of transcription initiation. Mol Cell 50, 420–9 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mechold U., Potrykus K., Murphy H., Murakami K. S. & Cashel M. Differential regulation by ppGpp versus pppGpp in Escherichia coli. Nucleic Acids Res 41, 6175–89 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Buglino J., Shen V., Hakimian P. & Lima C. D. Structural and biochemical analysis of the Obg GTP binding protein. Structure 10, 1581–92 (2002). [DOI] [PubMed] [Google Scholar]
  9. Mitkevich V. A. et al. Thermodynamic characterization of ppGpp binding to EF-G or IF2 and of initiator tRNA binding to free IF2 in the presence of GDP, GTP, or ppGpp. J Mol Biol 402, 838–46 (2010). [DOI] [PubMed] [Google Scholar]
  10. Milon P. et al. The nucleotide-binding site of bacterial translation initiation factor 2 (IF2) as a metabolic sensor. Proc Natl Acad Sci USA 103, 13962–7 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rymer R. U. et al. Binding mechanism of metalNTP substrates and stringent-response alarmones to bacterial DnaG-type primases. Structure 20, 1478–89 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Maciag M., Kochanowska M., Lyzen R., Wegrzyn G. & Szalewska-Palasz A. ppGpp inhibits the activity of Escherichia coli DnaG primase. Plasmid 63, 61–7 (2010). [DOI] [PubMed] [Google Scholar]
  13. Liu K. et al. Molecular mechanism and evolution of guanylate kinase regulation by (p)ppGpp. Mol Cell 57, 735–49 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gallant J., Irr J. & Cashel M. The mechanism of amino acid control of guanylate and adenylate biosynthesis. J Biol Chem 246, 5812–6 (1971). [PubMed] [Google Scholar]
  15. Shyp V. et al. Positive allosteric feedback regulation of the stringent response enzyme RelA by its product. EMBO Rep 13, 835–9 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dalebroux Z. D., Svensson S. L., Gaynor E. C. & Swanson M. S. ppGpp conjures bacterial virulence. Microbiol Mol Biol Rev 74, 171–99 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Haseltine W. A. & Block R. Synthesis of guanosine tetra- and pentaphosphate requires the presence of a codon-specific, uncharged transfer ribonucleic acid in the acceptor site of ribosomes. Proc Natl Acad Sci USA 70, 1564–8 (1973). [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Maisonneuve E., Castro-Camargo M. & Gerdes K. (p)ppGpp controls bacterial persistence by stochastic induction of toxin-antitoxin activity. Cell 154, 1140–50 (2013). [DOI] [PubMed] [Google Scholar]
  19. de la Fuente-Nunez C. et al. D-enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem Biol 22, 196–205 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. de la Fuente-Nunez C., Reffuveille F., Haney E. F., Straus S. K. & Hancock R. E. Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathog 10, e1004152 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mansour S. C., de la Fuente-Nunez C. & Hancock R. E. Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J Pept Sci 21, 323–9 (2015). [DOI] [PubMed] [Google Scholar]
  22. Andresen L., Tenson T. & Hauryliuk V. Cationic bactericidal peptide 1018 does not speci cally target the stringent response alarmone (p)ppGpp. Sci Rep 6, 36549 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Andresen L. et al. Auxotrophy-based High Throughput Screening assay for the identification of Bacillus subtilis stringent response inhibitors. Sci Rep 6, 35824 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wexselblatt E., Kaspy I., Glaser G., Katzhendler J. & Yavin E. Design, synthesis and structure-activity relationship of novel Relacin analogs as inhibitors of Rel proteins. Eur J Med Chem 70, 497–504 (2013). [DOI] [PubMed] [Google Scholar]
  25. Wexselblatt E. et al. Relacin, a novel antibacterial agent targeting the Stringent Response. PLoS Pathog 8, e1002925 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wexselblatt E. et al. ppGpp analogues inhibit synthetase activity of Rel proteins from Gram-negative and Gram-positive bacteria. Bioorg Med Chem 18, 4485–97 (2010). [DOI] [PubMed] [Google Scholar]
  27. O’Shea R. & Moser H. E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 51, 2871–8 (2008). [DOI] [PubMed] [Google Scholar]
  28. Steinchen W. & Bange G. The magic dance of the alarmones (p)ppGpp. Mol Microbiol 101, 531–44 (2016). [DOI] [PubMed] [Google Scholar]
  29. Ross W. et al. ppGpp Binding to a Site at the RNAP-DksA Interface Accounts for Its Dramatic Effects on Transcription Initiation during the Stringent Response. Mol Cell 62, 811–2 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Iyer R. P. Nucleobase protection of deoxyribo- and ribonucleosides. Curr Protoc Nucleic Acid Chem Chapter 2, Unit 2.1, 1–17 (2001). [DOI] [PubMed] [Google Scholar]
  31. Gaca A. O. et al. From (p)ppGpp to (pp)pGpp: Characterization of Regulatory Effects of pGpp Synthesized by the Small Alarmone Synthetase of Enterococcus faecalis. J Bacteriol 197, 2908–19 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. De Clercq E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond. Biochem Pharmacol 82, 99–109 (2011). [DOI] [PubMed] [Google Scholar]
  33. Keough D. T. et al. Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics. J Med Chem 52, 4391–9 (2009). [DOI] [PubMed] [Google Scholar]
  34. Kovackova S., Dracinsky M. & Rejman D. The synthesis of piperidine nucleoside analogs-a comparison of several methods to access the introduction of nucleobases. Tetrahedron 67, 1485–1500 (2011). [Google Scholar]
  35. Rejman D., Pohl R. & Dracinsky M. The Synthesis and Conformation of Dihydroxypiperidinyl Derivates of Nucleobases as Novel Iminosugar Nucleoside Analogs. European Journal of Organic Chemistry. 11, 2172–2187 (2011). [Google Scholar]
  36. Pohl R. et al. Synthesis, conformational studies, and biological properties of phosphonomethoxyethyl derivatives of nucleobases with a locked conformation via a pyrrolidine ring. Org Biomol Chem 13, 4693–705 (2015). [DOI] [PubMed] [Google Scholar]
  37. Rejman D. et al. N-Phosphonocarbonylpyrrolidine Derivatives of Guanine: A New Class of Bi-Substrate Inhibitors of Human Purine Nucleoside Phosphorylase. Journal of Medicinal Chemistry 55, 1612–1621 (2012). [DOI] [PubMed] [Google Scholar]
  38. Slavetinska L. P., Rejman D. & Pohl R. Pyrrolidine nucleotide analogs with a tunable conformation. Beilstein Journal of Organic Chemistry 10, 1967–1980 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Crumpacker C. S. Mechanism of action of foscarnet against viral polymerases. Am J Med 92, 3S–7S (1992). [DOI] [PubMed] [Google Scholar]
  40. Corrigan R. M., Bowman L., Willis A. R., Kaever V. & Grundling A. Cross-talk between two nucleotide-signaling pathways in Staphylococcus aureus. J Biol Chem 290, 5826–39 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. An S. Q. et al. A cyclic GMP-dependent signalling pathway regulates bacterial phytopathogenesis. EMBO J 32, 2430–8 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Arenz S. et al. The stringent factor RelA adopts an open conformation on the ribosome to stimulate ppGpp synthesis. Nucleic Acids Res 44, 6471–81 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Agirrezabala X. et al. The ribosome triggers the stringent response by RelA via a highly distorted tRNA. EMBO Rep 14, 811–6 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Paul B. J. et al. DksA: a critical component of the transcription initiation machinery that potentiates the regulation of rRNA promoters by ppGpp and the initiating NTP. Cell 118, 311–22 (2004). [DOI] [PubMed] [Google Scholar]
  45. Haugen S. P., Ross W. & Gourse R. L. Advances in bacterial promoter recognition and its control by factors that do not bind DNA. Nat Rev Microbiol 6, 507–19 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Parshin A. et al. DksA regulates RNA polymerase in Escherichia coli through a network of interactions in the secondary channel that includes Sequence Insertion 1. Proc Natl Acad Sci USA 112, E6862–71 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Zhang G. et al. Crystal structure of Thermus aquaticus core RNA polymerase at 3.3A resolution. Cell 98, 811–24 (1999). [DOI] [PubMed] [Google Scholar]
  48. Roghanian M., Zenkin N. & Yuzenkova Y. Bacterial global regulators DksA/ppGpp increase fidelity of transcription. Nucleic Acids Res 43, 1529–36 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Bernardo L. M., Johansson L. U., Solera D., Skarfstad E. & Shingler V. The guanosine tetraphosphate (ppGpp) alarmone, DksA and promoter affinity for RNA polymerase in regulation of sigma-dependent transcription. Mol Microbiol 60, 749–64 (2006). [DOI] [PubMed] [Google Scholar]
  50. Lambert P. A. Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria. J Appl Microbiol 92, 46S–54S (2002). [PubMed] [Google Scholar]
  51. Kriel A. et al. GTP dysregulation in Bacillus subtilis cells lacking (p)ppGpp results in phenotypic amino acid auxotrophy and failure to adapt to nutrient downshift and regulate biosynthesis genes. J Bacteriol 196, 189–201 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Srivatsan A. et al. High-precision, whole-genome sequencing of laboratory strains facilitates genetic studies. PLoS Genet 4, e1000139 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Nanamiya H. et al. Identification and functional analysis of novel (p)ppGpp synthetase genes in Bacillus subtilis. Mol Microbiol 67, 291–304 (2008). [DOI] [PubMed] [Google Scholar]
  54. Cutting S. M. & Horn P. B. V. In Molecular biological methods for Bacillus (eds Hardwood C. R. & Cutting S. M.) (Cutting, New York, 1990). [Google Scholar]
  55. Brown A., Fernandez I. S., Gordiyenko Y. & Ramakrishnan V. Ribosome-dependent activation of stringent control. Nature 534, 277–80 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Oki T., Yoshimoto A., Sato S. & Takamatsu A. Purine nucleotide pyrophosphotransferase from Streptomyces morookaensis, capable of synthesizing pppApp and pppGpp. Biochim Biophys Acta 410, 262–72 (1975). [DOI] [PubMed] [Google Scholar]
  57. Mukai J. & Koguchi S. Effects of purine and pyrimidine nucleoside 5′-di(tri) phosphate-3′-diphosphates on the Escherichia coli cell-free transcription and translation activity. FEBS Lett 141, 251–3 (1982). [DOI] [PubMed] [Google Scholar]
  58. Antoun A., Pavlov M. Y., Tenson T. & Ehrenberg M. M. Ribosome formation from subunits studied by stopped-flow and Rayleigh light scattering. Biol Proced Online 6, 35–54 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Mechold U., Murphy H., Brown L. & Cashel M. Intramolecular regulation of the opposing (p)ppGpp catalytic activities of Rel(Seq), the Rel/Spo enzyme from Streptococcus equisimilis. J Bacteriol 184, 2878–88 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Sebaugh J. L. Guidelines for accurate EC50/IC50 estimation. Pharm Stat 10, 128–34 (2011). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep41839-s1.pdf (2.7MB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES